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creativecommons.org/licenses/by-nc-nd/Abstract Recent randomised phase II trial data have indicated that the addition of olaratu-
mab, a novel monoclonal antibody against platelet-derived growth factor receptor alpha
(PDGFRa), to doxorubicin confers an unprecedented improvement in overall survival to pa-
tients with anthracycline-naı¨ve advanced soft tissue sarcoma. However, this result was dispro-
portionate with progression-free survival and response rate, and consequently there are
unanswered questions regarding the precise mechanism of action of olaratumab. While pre-
clinical data show that olaratumab specifically inhibits PDGFRa-mediated oncogenic signal-
ling with attendant anti-tumour effects, a lack of correlation between pharmacodynamics
markers of PDGFRa inhibition and clinical benefit from olaratumab suggest other mecha-
nisms beyond modulation of downstream PDGFRa molecular pathways. Proposed mecha-
nisms of olaratumab activity include engagement of anti-tumour immune responses and
alterations of the tumour stroma, but these require further evaluation. Meanwhile, the
drug-specific contribution of cytotoxic agents to olaratumab-containing combinations has
yet to be characterised. Ongoing and future preclinical and translational studies, coupled with
the anticipated results of a phase III trial that has completed enrolment, should provide
greater insight into the efficacy and mode of action of olaratumab in soft tissue sarcomas.
ª 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).t, Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK. Fax: þ44 207 808 2113.
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Soft tissue sarcomas (STS) are a group of rare and het-
erogeneous malignant tumours of mesenchymal origin
that represent around 1% of adult malignancy and
encompass a broad range of clinical phenotype and un-
derlying biology. Doxorubicin-based chemotherapy has
been the standard for first-line treatment of advanced STS
for decades, with associated median overall survival (OS)
consistently reported at 12e18 months [1]. Meanwhile,
over 20 years of clinical studies in advanced STS have
rarely provided definitive evidence of survival benefit for
investigative agents [2e5]. However, in July 2016, a major
breakthrough was achieved by the results of the JGDG
study. In this open label phase Ib and randomised phase II
trial, olaratumab, a monoclonal antibody (mAb) directed
against platelet-derived growth factor receptor-alpha
(PDGFRa), was combined with standard doxorubicin
chemotherapy in anthracycline-naı¨ve advancedSTS [6]. In
the phase II component, a near-doubling of median OS
was seen in patients who received combined olar-
atumabedoxorubicin, leading to the accelerated approval
of olaratumab in this setting. However, a discrepancy
between a large improvement in OS and only modest
improvement in disease control end-points in the JGDG
trial has given rise to unanswered questions regarding the
activity of olaratumab. In this perspective article, we
outline the therapeutic rationale and clinical data for
olaratumab in advanced STS, before exploring potential
explanations for the unresolved enigma of an agent that
appears to confer a highly significant survival benefit
without a corresponding improvement in disease control.2. Olaratumab: a novel PDGFRa-targeting antibody
PDGFRa is a receptor tyrosine kinase (RTK) that en-
gages downstream pathways that play important roles in
mesenchymal stem cell differentiation and vascular
endothelial growth factoremediated angiogenesis [7].
Overexpression and activating mutations of PDGFRA
in cancer have been shown to contribute to tumour
development, proliferation, metastasis and establish-
ment of a tumour-supporting microenvironment [8e10].
In STS, increased tumour expression of PDGFRa cor-
responds with higher histological grades and poor
prognosis [11]. A range of tyrosine kinase inhibitors
with activity against PDGFRa have been evaluated in
advanced STS, whereas pazopanib attained approval in
the post-1st line setting based on phase III trial evidence
of progression-free survival (PFS); but not OS benefit
over placebo, a number of other related agents have
demonstrated generally disappointing efficacy [12,13].
Olaratumab is a human immunoglobulin G subclass
1 mAb with selective, high affinity binding to the
extracellular domain of PDGFRa, disrupting receptor-
ligand interactions with resulting downregulation ofdownstream signal transduction [6,7,14]. Olaratumab
has in vitro and in vivo activity in reducing proliferation
and progression of numerous cancer cell lines including
sarcomas [14,15]. In addition, combination of olar-
atumab with doxorubicin resulted in greater inhibition
of tumour growth compared with doxorubicin alone in
xenograft models of human osteosarcoma [16].
Two open-label dose-escalation Phase I studies eval-
uated olaratumab as a single agent in patients with
advanced solid tumours (Table 1). In both the earlier
U.S. and later Japanese studies, the drug was well
tolerated and without dose-limiting toxicities [17,18]
(Tables 1 and 2). No objective radiological responses
were observed in either studyda best response of stable
disease was seen in 12 (63%) patients in the US phase I,
and in 7 (44%) patients in the Japanese trial.
Based on preclinical evidence of potential synergy with
doxorubicin, the combination of olaratumab with
chemotherapy was investigated in advanced STS in the
JGDGstudy.Fifteenpatientswere enrolled in thephase Ib
component, and all were treated with olaratumab (15 mg/
kg on D1þD8 q3w) and doxorubicin (75 mg/m2 on D1
q3w) for up to eight cycles, with the addition of dexra-
zoxane during cycles 5e8, at the discretion of the treating
investigator. Patients then continued with olaratumab
monotherapy until disease progression. Having satisfac-
torilymet the primary safety end-points of the initial phase
1 b stage, the study rolled out to an open-label phase II
stage, with patients randomised 1:1 to receive doxorubicin
alone or in combination with olaratumab as per phase Ib
schedule. The phase II study was designed to detect a 50%
improvement inmedianPFS (hazard ratio [HR] 0.67)with
80% power and two-sided significance level of 0.20.
In the intention-to-treat (ITT) analysis of 133 rand-
omised patients, a significant improvement in the pri-
mary end-point of investigator-assessed PFS was seen in
the olaratumabedoxorubicin arm, albeit at the pre-
stated significance level (HR 0.672, 95% confidence in-
terval [CI] 0.442e1.021, p Z 0.0615), while there was a
non-significant increase in objective response rate from
11.9% to 18.2% between control and investigational
arms respectively (p Z 0.34). However, the 2-month
improvement in median PFS (4.1 months in the control
arm vs. 6.6 months in olaratumab arm) was dwarfed by
a 12-month improvement in median OS (14.7 vs 26.5
months; OS HR 0.46; 95% CI 0.30e0.71; p Z 0.0003).
OS benefit from olaratumab-containing therapy was
seen across all analysed pre-planned and post-hoc sub-
groups, including prospectively stratified leiomyo-
sarcoma vs. other histological subtype subgroups.
Prospective IHC assessment of tumour PDGFRa
expression was performed using an assay later recog-
nised as being insufficiently specific. A post-hoc repeat
analysis of tumour PDGFRa using a more specific IHC
assay found that most enrolled patients’ tumours (67%)
were PDGFRa negative, whereas PDGFRa expression
was not found to be associated with OS or PFS.
Table 1
Summary of selected toxicities from reported clinical trials of olaratumab.
Trial Phase I single
agent olaratumab
Phase I single agent
olaratumab
Randomised open-label phase II in anthracycline-naive
advanced STS
Randomised open-label phase II in untreated advanced
NSCLC
Arm Olaratumab (N Z 19) Olaratumab (N Z 16) Olaratumab þ doxorubicin
(N Z 64)
Doxorubicin
(N Z 65)
Olaratumab þ paclitaxelecarboplatin
(N Z 67)
Paclitaxelecarboplatin
(N Z 64)
Any grade G3-4 Any grade G3-4 Any grade G3-4 Any grade G3-4 Any grade G3-4 Any grade G3-4
Any AEs 18 (95) 1 (5) 16 (100) 1 (6) 63 (98) 51 (80) 64 (98) 45 (69) 67 (100) 54 (81) 64 (100) 40 (63)
TRAEs 8 (42) 1 (5) 8 (50) 1 (6) 33 (98) 43 (67) 63 (97) 36 (55) NR NR NR NR
SAEs 9 (47) 0 2 (13) 2 (13) 27 (42) 27 (42) 25 (38) 22 (34) 30 (45) 27 (40) 19 (30) 17 (27)
Anaemia 0 0 1 (6) 0 26 (41) 8 (13) 24 (37) 6 (9) 23 (34) 4 (6) 27 (42) 6 (9)
Thrombocytopaenia 1 (5) 0 0 0 NR NR NR NR 29 (43) 9 (13) 15 (23) 3 (5)
Neutropaenia 0 0 1 (6) 0 37 (58) 24 (38) 23 (35) 21 (32) 35 (52) 25 (37) 21 (33) 14 (22)
Febrile Neutropaenia 0 0 0 0 8 (13) 8 (13) 9 (14) 9 (14) 4 (6) 4 (6) 1 (2) 1 (2)
Infusion reaction 2 (11) 0 0 0 8 (13) 2 (3) 0 0 17 (25) 1 (2) 5 (8) 1 (2)
Pyrexia 1 (5) 0 1 (6) 0 15 (23) 0 12 (18) 0 NR NR NR NR
Vomiting 1 (5) 0 0 0 29 (45) 0 12 (18) 0 28 (42) 0 22 (34) 0
Diarrhoea 1 (5) 0 1 (6) 0 22 (34) 2 (3) 15 (23) 0 29 (43) 2 (3) 19 (30) 0
Mucositis 0 0 0 0 34 (53) 2 (3) 23 (35) 3 (5) 19 (28) 1 (2) 10 (16) 0
Fatigue 2 (11) 0 1 (6) 0 44 (69) 6 (9) 45 (69) 2 (3) 43 (64) 7 (10) 33 (52) 2 (3)
Evidence of cardiac
dysfunction
NR NR NR NR 15 (23) 1 (2) 11 (17) 0 NR NR NR NR
Other: G3:
Raised serum ALP 1 (5)
G1-2:
Constipation 1(5)
Chills 1(5)
Headache 1(5)
Tumour haemorrhage 1(5)
G3:
Tumour haemorrhage 1 (6)
Raised serum AST 1(6)
G1-2:
Proteinuria 4 (25)
Raised serum AST 2 (13)
Anorexia 1 (6)
Constipation 1 (6)
Cough 1 (6)
Dermatitis 1(6)
Hyperglycaemia 1 (6)
Rash 1 (6)
Abbreviations: AE, adverse event; ALP, alkaline phosphatase; AST, aspartate aminotransferase; NR, not reported; SAE, serious adverse event; TRAE, treatment-related adverse event.
Frequency of AEs expressed as number (%).
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Table 2
Early-phase clinical trials of olaratumab.
Study Phase/cohort Feature N Treatment Dosage (mg/kg) Schedule
JGDC Phase I/1 Solid tumour 5 Olaratumab 4 Weekly (4/2)
Phase I/2 3 8 Weekly (4/2)
Phase I/3 5 16 Weekly (4/2)
Phase I/4 3 15 Biweekly
Phase I/5 3 20 Biweekly
JGDF Phase I/1 Japanese Solid tumour 3 Olaratumab 10 D1eD8, q3w
Phase I/2 Japanese 7 20 Biweekly
Phase I/3 Japanese 3 15 D1eD8, q3w
JGDG Phase II/experimental Soft Tissue Sarcomas 79 Olaratumab þ doxorubicine 15 mg/kg þ 75 mg/m2 D1eD8, q3w
D1, q3w
Phase II/control 65 Doxorubicine 75 mg/m2 D1eD8, q3w
Abbreviations: STS, soft tissue sarcomas; D, day; q3w, every 3 weeks.
G. Antoniou et al. / European Journal of Cancer 92 (2018) 33e3936Safety data from the JGDG trial indicated an increased
rate of severe toxicity associated with the addition of
olaratumab to doxorubicin, with 67% of patients treated
in the investigational arm experiencing a grade 3e4
treatment-related adverse event, compared with 55% in
the monotherapy arm (Table 1), a difference largely
accounted for by an excess of fatigue and haematological
toxicity that did not translate into a significant difference
in febrile neutropaenia. Of note, there was a small excess
of non-severe cardiac dysfunction in the olaratumab arm
(23% vs 17%)dthe increase in this consolidated cardiac
measure was primarily due to a higher incidence of grade
1e2 peripheral oedema. Treatment discontinuations due
to toxicity and deaths were infrequent and evenly
balanced across both arms. Quality-of-life data were not
collected during the JGDG study.
3. Unanswered questions
The efficacy data from the JGDG trial undoubtedly
indicate that olaratumab is a promising agent for the
treatment of advanced STS. Furthermore, the inclusion
of patients with a variety of different STS histotypes and
performance status of 2 or less is representative of real-
life clinical practice and, with doxorubicin as a
comparator, allow for direct conclusions. However,
these randomised phase II results must be carefully
interpreted, particularly given the lack of intuitive as-
sociation of an improved life expectancy with increased
delay in disease progression. Early-phase studies are
subject to selection, surveillance and publication bias,
contributing to the frequent failure to replicate early-
phase outcomes in subsequent larger randomised studies
[19]. Meanwhile, although data are awaited from the
ANNOUNCE III study, a subsequent double-blinded
phase III trial that mirrors the design of JGDG, a
number of key questions regarding olaratumab remain:
1. What is the explanation for the mismatched degree of OS
and PFS gains in the JGDG study?
Although PFS is a widely used end-point and accepted
by regulatory bodies as a legitimate efficacymeasure, it is asubjective measure that is vulnerable to bias in open label
trials, a fact that likely contributes to instances of poor
correlation between PFS and OS [20]. PFS may underes-
timate the benefit of treatments associated with unusual
patterns of response, such as in the case of immune-
mediated pseudo-progression resulting in PFS data
significantly underestimating the survival benefit of ipili-
mumab in advanced melanoma. Data regarding patterns
of radiological response to olaratumab-containing treat-
ment are currently not available, but given previously
noted inadequacies of RECIST in the assessment of STS
and the possibility of an antibody-dependent cell-medi-
ated cytotoxicity (ADCC) component of olaratumab ef-
fect, unanticipated phenomena such as immune-related
responses cannot yet be ruled out [21].
A recent clinical trial of eribulin, a microtubule inhibi-
tor, in advanced STS reported initial survival data similar
to that of the JGDG trial [22]. In this open label phase III
RCT, patients with previously treated advanced leio-
myosarcoma or liposarcoma were randomised to receive
either eribulin or dacarbazine. Results from all 452 rand-
omised patients demonstrated improvement in OS with
eribulin (HR 0.77, 95% CI 0.62e0.95, pZ 0.0169) but no
difference in PFS and radiological response rates between
the two arms. However, subgroup analysis of this trial has
since identified that efficacy of eribulin is largely limited to
patients with liposarcoma, in whomHRs for PFS and OS
show an almost identical degree of eribulin benefit (HR
0.52 and 0.51 respectively) [23]. Available subtype-specific
efficacy data for olaratumab is currently limited, with the
JGDG trial reporting no difference in olaratumab benefit
between leiomyosarcoma and heterogenous ‘other’ sub-
groups. Further analysis of results from the JGDG study
and forthcoming phase III data may yet identify a histo-
logical subgroup in which olaratumab benefit is enriched.
Alternatively, translational studies may identify biologi-
cally defined molecular subgroups that transcend histo-
logical classifications and exhibit differential sensitivity to
olaratumab-based therapy.
Post-trial therapy can introduce imbalances between
hitherto controlled trial arms. Systematic biases that see
patients from one arm enjoying greater access to effective
post-trial treatments could result in divergent OS in the
Table 3
Current trials of olaratumab.
Title Phase Study design Conditions Interventions Recruitment Study results URL
1 A study of olaratumab
(LY3012207) plus pembrolizumab
in participants with advanced or
metastatic soft tissue sarcoma
1 Non-randomised
Open label
Soft tissue
sarcoma
Olaratumab þ pembrolizumab Recruiting No results available https://ClinicalTrials.gov/show/NCT03126591
2 A study of olaratumab in soft
tissue sarcoma
1/2 Randomised
Open label
Soft tissue
sarcoma
Olaratumab þ doxorubicin Completed Has results https://ClinicalTrials.gov/show/NCT01185964
3 A study of olaratumab
(LY3012207) in participants with
soft tissue sarcoma
1 Single group
Open label
Soft tissue
sarcoma
Olaratumab þ doxorubicin Recruiting No results available https://ClinicalTrials.gov/show/NCT02783599
4 A study of olaratumab
(LY3012207) in participants with
advanced soft tissue sarcoma
(ANNOUNCE II)
1/2 Double-blind
randomised
Soft tissue
sarcoma
Olaratumab/placebo þ
gemcitabine þ docetaxel
Recruiting No results available https://ClinicalTrials.gov/show/NCT02659020
5 A study of doxorubicin plus
olaratumab (LY3012207) in
participants with advanced or
metastatic soft tissue sarcoma
(ANNOUNCE III or JGDJ)
3 Double-blind
randomised
Soft tissue
sarcoma
Olaratumab/placebo þ
doxorubic
Active,
not recruiting
No results available https://ClinicalTrials.gov/show/NCT02451943
6 A study of olaratumab and
doxorubicin in participants with
advanced soft tissue sarcoma
1 Non-randomised
Open label
Soft tissue
sarcoma
Olaratumab þ doxorubicin Active,
not recruiting
No results available https://ClinicalTrials.gov/show/NCT02326025
7 doxorubicin with upfront
dexrazoxane plus olaratumab for
the treatment of advanced or
metastatic soft tissue sarcoma
2 Non-randomised
Open label
Soft tissue
sarcoma
Dexrazoxane þ doxorubicin þ
olaratumab
Recruiting No results available https://ClinicalTrials.gov/show/NCT02584309
8 A study of olaratumab
(LY3012207), doxorubicin, and
ifosfamide in participants with
advanced or metastatic soft tissue
sarcoma
1 Single group
Open label
Soft tissue
sarcoma
Olaratumab þ
Doxorubicin þ
Ifosfamide þ
Mesna
Not yet
recruiting
No results available https://ClinicalTrials.gov/show/NCT03283696
9 A study of olaratumab in Japanese
participants with advanced cancer
1 Non-randomised
Open label
Neoplasms Olaratumab þ doxorubicin Active,
not recruiting
No results available https://ClinicalTrials.gov/show/NCT02377752
Trials taken from U.S. National Library of Medicine, U.S. National Institutes of Health and U.S. Department of Health & Human Services.
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G. Antoniou et al. / European Journal of Cancer 92 (2018) 33e3938absence of differences in PFS, an end-point that is immune
to post-trial contamination. In the JGDG trial, data on
post-trial treatment was collected for all patients in the
ITT cohort. Overall, more patients from the olaratumab-
containing arm received any post-trial treatment (67% vs
49%), although not counted in this number were 30 pa-
tients in the doxorubicin arm who, per protocol, crossed
over to olaratumab monotherapy at disease progression.
This crossover to an agent with little demonstrated single-
agent efficacy may have limited or delayed the access of
patients in the control arm to potentially more effective
standard post-trial therapies. More patients from the
olaratumab arm went on to receive gemcitabine and
docetaxel (10.5% vs 6.0%), trabectedin (8.3% vs 2.3%) and
pazopanib (11.3% vs 7.5%), all agents of recognised ac-
tivity in STS. However, this imbalance might at least be
partly explained if patients who received an incrementally
active investigational regimen attained greater fitness and
life expectancy, and thus were better positioned to be
considered for further treatment.
2. What is the precise mechanism of olaratumab action in
STS?
Given the disruption of ligand interaction and down-
stream signalling of PDGFRa on drug binding, it might
be anticipated that the anticancer effect of olaratumab
would be via direct inhibition of PDGFRa-driven
oncogenicity. Olaratumab has been shown to inhibit
ligand-induced phospho-activation of PDGFRa, with
attendant reduction in proliferation and invasion across a
number of PDGFRa-expressing sarcoma cell lines.
Effective inhibition of PDGFRa by olaratumab is indi-
cated by clinical pharmacodynamic data that demon-
strate an expected increase in circulating platelet-derived
growth factors (PDGFs), cognate ligands of PDGFRa
[18,24]. However, the degree of PDGF increase showed
no association with anti-tumour efficacy in phase I
studies, as was the case with tumour PDGFRa expression
in the JGDG study. Absence of differences between
PDGFRa positive and negative tumours suggests that
PDGFRa inhibition is not the sole mechanism of olar-
atumab action. Conversely, in other cancer settings where
mAbs against oncogenic RTK drivers are established
standards of care, expression level of the targeted RTK
may either have a strong association or no association
with drug efficacy, such as the respective cases of Her2-
targeting mAbs in breast cancer and EGFR-targeting
mAbs in colorectal or head and neck cancers [25e27].
In addition, it is increasingly recognised that the activity
of such drugs is partly through the engagement of an
ADCC-mediated anti-tumour response [28]. Should this
be the case with olaratumab in STS, the observed
discrepancy in degree of effect on PFS and OS may also
lie within the very properties of the drug itself.
PDGFRa inhibition reduces the tumour interstitial
pressure, resulting in an elevated blood flow within thetumour, thereby potentially improving the delivery and
tumour uptake of doxorubicin [9]. The JGDG study
only tested the tumour PDGFRa expression, but not the
stromal expression, which may be a key point of its
mechanism. The authors of the study hypothesised that
olaratumab may confer persistent alterations in the host
stromal component of the tumour microenvironment
that results in a pre-sensitisation of tumour to subse-
quent cytotoxic therapies, and thus explaining the
disparity between PFS and OS benefitdat present,
direct evidence of such a mechanism is lacking.
3. What is the therapeutic interaction between cytotoxic
chemotherapy and PDGFRa inhibition?
The importance of the cytotoxic component to the ef-
ficacy of combination olaratumabedoxorubicin is indi-
cated by the lack of evidence of single-agent activity of the
mAb [17,18]. However, data regarding the drug-specific
interaction of olaratumab with any given chemothera-
peutic are lacking. So far, clinical trials of olaratumab-
chemotherapy combinations have been informed by
pre-existing standards of care, as seen with the choice of
doxorubicin in the JGDG and ANNOUNCE III trials,
carboplatin and paclitaxel in a reported randomised phase
II trial in advanced none-small-cell lung cancer, and the
use of gemcitabine-docetaxel or doxorubicin-ifosfamide
backbones in ongoing studies in STS [29] (Table 3). If
the principal mechanism of action of olaratumab is via
stromal interactions, then this may result in improved
microenvironment pharmacokinetics that is generic to
many different cytotoxic drugs. However, given the rec-
ognised diversity of different cytotoxic agents in terms of
effects on vascular remodelling and immunomodulation, it
would seem likely that different drugs would exhibit
qualitatively different interactions with olaratumab, thus
making choice of combination an important clinical fac-
tor. Further in vitro and in vivo investigation of the additive
anti-tumour potential of such chemo-mAb combinations
is required across STS and other cancer models to provide
greater rationale for future clinical protocols.
4. Conclusions
Despite concerted investigation of many novel agents,
treatment options for advanced STS have remained
limited. In this context, initial clinical results associated
with olaratumabedoxorubicin treatment are the source
of considerable excitement. Furthermore, the potential
of olaratumab to provide benefit as part of adjuvant
treatment of early-stage disease presents a worthwhile
avenue of investigation. However, in the context of the
high cost (estimated price per quality-adjusted life
year £46,000e60,000 [30]) and toxicity associated with
this novel regimen, it is crucial that definitive evidence of
survival benefit, improvement of quality of life and cost
effectiveness is obtaineddthe highly anticipated results
G. Antoniou et al. / European Journal of Cancer 92 (2018) 33e39 39from the ANNOUNCE III trial, expected in late 2020,
should provide valuable data. Meanwhile, key trans-
lational research questions regarding the mechanism of
action of olaratumab must be tackled to inform how
best to employ this promising agent in the treatment of
advanced STS and other cancers.
Conflict of interest statement
None declared.
References
[1] Linch M, Miah AB, Thway K, Judson IR, Benson C. Systemic
treatment of soft-tissue sarcoma-gold standard and novel thera-
pies. Nat Rev Clin Oncol 2014;11:187e202.
[2] Ryan CW, Merimsky O, Agulnik M, Blay JY, Shuetze SM, Van
Tine BA, et al. PICASSO III: a phase III, placebo-controlled study
of doxorubicin with or without palifosfamide in patients with
metastatic soft tissue sarcoma. J Clin Oncol 2016;34:3898e905.
[3] Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F,
et al. Gemcitabine and docetaxel versus doxorubicin as first-line
treatment in previously untreated advanced unresectable or met-
astatic soft-tissue sarcomas (GeDDiS): a randomised controlled
phase 3 trial. Lancet Oncol 2017;0.
[4] Tap WD, Papai Z, Van Tine BA, Attia S, Ganjoo KN, Jones RL,
et al. Doxorubicin plus evofosfamide versus doxorubicin alone in
locally advanced, unresectable or metastatic soft-tissue sarcoma
(TH CR-406/SARC021): an international, multicentre, open-
label, randomised phase 3 trial. Lancet Oncol 2017;18:1089e103.
[5] Lee ATJ, Pollack SM, Huang P, Jones RL. Phase III soft tissue
sarcoma trials: success or failure? Curr Treat Options Oncol 2017;
18:19.
[6] Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD,
Adkins D, et al. Olaratumab and doxorubicin versus doxorubicin
alone for treatment of soft-tissue sarcoma: an open-label phase 1b
and randomised phase 2 trial. Lancet 2016;388:488e97.
[7] Demoulin J-B, Essaghir A. PDGF receptor signaling networks in
normal and cancer cells. Cytokine Growth Factor Rev 2014;25:
273e83.
[8] Ostman A, Heldin C-H. PDGF receptors as targets in tumor
treatment. Adv Canc Res 2007;97:247e74.
[9] Pietras K, Rubin K, Sjo¨blom T, Buchdunger E, Sjo¨quist M,
Heldin CH, et al. Inhibition of PDGF receptor signaling in tumor
stroma enhances antitumor effect of chemotherapy. Canc Res
2002;62:5476e84.
[10] Thiery JP, Acloque H, Huang RYJ, Nieto MA. Epithelial-
mesenchymal transitions in development and disease. Cell 2009;
139:871e90.
[11] Kilvaer TK, Smeland E, Valkov A, Sorbye SW, Bremnes RM,
Busund LT, et al. The VEGF- and PDGF-family of angiogenic
markers have prognostic impact in soft tissue sarcomas arising in
the extremities and trunk. BMC Clin Pathol 2014;14:5.
[12] van der Graaf WTA, Blay JY, Chawla SP, Kim DW, Bui-
Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue
sarcoma (PALETTE): a randomised, double-blind, placebo-
controlled phase 3 trial. Lancet 2012;379:1879e86.
[13] Frezza AM, Stacchiotti S, Gronchi A. Systemic treatment in
advanced soft tissue sarcoma: what is standard, what is new.
BMC Med 2017;15:109.
[14] Loizos N, Xu Y, Huber J, Liu M, Lu D, Finnerty B, et al. Tar-
geting the platelet-derived growth factor receptor alpha with a
neutralizing human monoclonal antibody inhibits the growth of
tumor xenografts: implications as a potential therapeutic target.
Mol Canc Ther 2005;4:369e79.[15] Stock P, Monga D, Tan X, Micsenyi A, Loizos N, Monga SP.
Platelet-derived growth factor receptor-alpha: a novel therapeutic
target in human hepatocellular cancer. Mol Canc Ther 2007;6:
1932e41.
[16] Deevi DS, Lariccia L,Wang S, Joynes C, Steiner P, Bruheim S, et al.
Inhibitionofhumanosteosarcomaxenograft growthbyanti-Platelet
derived growth factor receptor alpha antibody, IMC-3G3, alone and
in combination with chemotherapy. Canc Res 2006;66. 877e877.
[17] Chiorean EG, Sweeney C, Youssoufian H, Qin A,
Dontabhaktuni A, Loizos N, et al. A phase I study of olaratumab,
an anti-platelet-derived growth factor receptor alpha (PDGFRa)
monoclonal antibody, in patients with advanced solid tumors.
Canc Chemother Pharmacol 2014;73:595e604.
[18] Doi T, Ma Y, Dontabhaktuni A, Nippgen C, Nippgen J,
Ohtsu A. Phase I study of olaratumab in Japanese patients with
advanced solid tumors. Canc Sci 2014;105:862e9.
[19] Zia MI, Siu LL, Pond GR, Chen EX. Comparison of outcomes of
phase II trials (P2Ts) and subsequent randomized control trials
(RCTs) using identical therapeutic regimens. J Clin Oncol 2004;
22. 6000e6000.
[20] Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C,
et al. Ipilimumab plus dacarbazine for previously untreated
metastatic melanoma. N Engl J Med 2011;364:2517e26.
[21] Stacchiotti S, Collini P, Messina A, Morosi C, Barisella M,
Bertulli R, et al. High-grade soft-tissue sarcomas: tumor response
assessmentdpilot study to assess the correlation between radio-
logic and pathologic response by using RECIST and choi criteria.
Radiology 2009;251:447e56.
[22] Scho¨ffski P, Chawla S, Maki RG, Italiano A, Gelderblom H,
Choy E, et al. Eribulin versus dacarbazine in previously treated
patients with advanced liposarcoma or leiomyosarcoma:
a randomised, open-label, multicentre, phase 3 trial. Lancet
(London, England) 2016;387:1629e37.
[23] Demetri GD, Scho¨ffski P, Grignani G, Blay JY, Maki RG, Van
Tine BA, et al. Activity of eribulin in patients with advanced
liposarcoma demonstrated in a subgroup analysis from a ran-
domized phase III study of eribulin versus dacarbazine. J Clin
Oncol 2017;35:3433e9.
[24] Lowery CD, Blosser W, Dowless M, Knoche S, Stephens J, Li H,
et al. Olaratumab exerts anti-tumor activity in preclinical models
of pediatric bone and soft tissue tumors through inhibition of
platelet-derived growth factor receptor & alpha. Clin Cancer Res
2017. https://doi.org/10.1158/1078-0432.CCR-17-1258.
clincanres.1258.2017.
[25] Gasol Cudo´s A, Morales S, Novell Alvarez A, Serrate Lopez A,
Velasco Sanchez A, Salud Salvia A. Pathological complete
response in HER2 positive breast cancer treated with trastuzumab
and chemotherapy: predictive factors report. J Clin Oncol 2017;
35. e12133ee12133.
[26] Asghar U, Hawkes E, Cunningham D. Predictive and prognostic
biomarkers for targeted therapy in metastatic colorectal cancer.
Clin Colorectal Canc 2010;9:274e81.
[27] Bossi P, Resteghini C, Paielli N, Licitra L, Pilotti S, Perrone F.
Prognostic and predictive value of EGFR in head and neck
squamous cell carcinoma. Oncotarget 2016;7:74362e79.
[28] Kroemer G, Senovilla L, Galluzzi L, Andre´ F, Zitvogel L. Nat-
ural and therapy-induced immunosurveillance in breast cancer.
Nat Med 2015;21:1128e38.
[29] Gerber DE, Swanson P, Lopez-Chavez A, Wong L, Dowlati A,
Pennell NA, et al. Phase II study of olaratumab with paclitax-
el/carboplatin (P/C) or P/C alone in previously untreated
advanced NSCLC. Lung Canc 2017;111:108e15.
[30] Tikhonova IA, Jones-Highes T, Dunham J, Warren FC,
Robinson S, Stephens P, et al. Olaratumab in combination with
doxorubicin for the treatment of advanced soft tissue sarcoma: an
evidence review group perspective of a national institute for
health and care excellence single technology appraisal. Pharma-
coeconomics 2017. https://doi.org/10.1007/s40273-017-0568-3.
